ALNY Alnylam Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ALNY
Price (delayed)
$434.56
Market cap
$57.41B
P/E Ratio
1,401.81
Dividend/share
N/A
EPS
$0.31
Enterprise value
$59.13B
Relative Growth:
Rel. Growth:
96
Relative Strength:
Rel. Strength:
83
Relative Valuation:
Rel. Valuation:
7
Relative Profitability:
Rel. Profitability:
85
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is
Highlights
The company's net income has surged by 114% QoQ and by 113% YoY
ALNY's EPS has surged by 113% since the previous quarter and by 112% year-on-year
The debt has grown by 18% YoY and by 2.1% from the previous quarter
The company's quick ratio fell by 10% QoQ and by 8% YoY
Key stats
What are the main financial stats of ALNY
Market
Valuations
Earnings
Shares outstanding
132.11M
Market cap
$57.41B
Enterprise value
$59.13B
Price to earnings (P/E)
1,401.81
Price to book (P/B)
243.54
Price to sales (P/S)
17.79
PEG
12.53
EV/EBIT
453.77
EV/EBITDA
389.23
EV/Sales
18.42
Revenue
$3.21B
Gross profit
$2.69B
Operating income
$264.7M
Net income
$43.57M
EBIT
$130.32M
EBITDA
$151.92M
Free cash flow
$221.36M
Per share
Balance sheet
Liquidity
EPS
$0.31
EPS diluted
$0.24
Free cash flow per share
$1.68
Book value per share
$1.78
Revenue per share
$24.42
TBVPS
$36.91
Total assets
$4.85B
Total liabilities
$4.62B
Debt
$3.21B
Equity
$233.89M
Working capital
$2.4B
Debt to equity
13.74
Current ratio
2.54
Quick ratio
2.37
Net debt/EBITDA
11.34
Margins
Efficiency
Dividend
EBITDA margin
4.7%
Gross margin
83.9%
Net margin
1.4%
Operating margin
8.2%
Return on assets
1%
Return on equity
26.1%
Return on invested capital
2.5%
Return on capital employed
4%
Return on sales
4.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALNY stock price
How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
2.62%
1 week
-9.77%
1 month
-4.77%
1 year
63.81%
YTD
84.68%
QTD
-4.7%
Financial performance
How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$3.21B
Gross profit
$2.69B
Operating income
$264.7M
Net income
$43.57M
Gross margin
83.9%
Net margin
1.4%
The company's operating margin has surged by 191% YoY
The company's net income has surged by 114% QoQ and by 113% YoY
The net margin has soared by 111% from the previous quarter and by 109% YoY
The company's revenue has surged by 53% YoY and by 30% QoQ
Price vs fundamentals
How does ALNY's price correlate with its fundamentals
Growth
What is Alnylam Pharmaceuticals's growth rate over time
Valuation
What is Alnylam Pharmaceuticals stock price valuation
P/E
1,401.81
P/B
243.54
P/S
17.79
EV/EBIT
453.77
EV/EBITDA
389.23
EV/Sales
18.42
ALNY's EPS has surged by 113% since the previous quarter and by 112% year-on-year
ALNY's price to book (P/B) is 17% less than its last 4 quarters average of 295.1
The equity has contracted by 7% from the previous quarter
The company's revenue has surged by 53% YoY and by 30% QoQ
ALNY's price to sales (P/S) is 13% lower than its 5-year quarterly average of 20.4 but 10% higher than its last 4 quarters average of 16.1
Efficiency
How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on invested capital has surged by 163% year-on-year and by 156% since the previous quarter
ALNY's return on sales has surged by 146% year-on-year and by 145% since the previous quarter
The return on assets has surged by 114% since the previous quarter and by 112% year-on-year
The ROE has soared by 110% from the previous quarter
Dividends
What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALNY.
Financial health
How did Alnylam Pharmaceuticals financials performed over time
The total assets is 5% more than the total liabilities
The total assets has increased by 15% YoY and by 6% from the previous quarter
The company's total liabilities rose by 11% YoY and by 7% QoQ
Alnylam Pharmaceuticals's debt to equity has plunged by 84% YoY but it has increased by 9% from the previous quarter
The debt has grown by 18% YoY and by 2.1% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.